FDA MedWatch - Lidocaine HCl Topical Solution 4% by Teligent Pharma:

Recall - Due to Super Potency

MedWatch - The FDA Safety Information and Adverse Event Reporting Program TOPIC: Lidocaine HCl Topical Solution 4% by Teligent Pharma: Recall - Due to Super Potency AUDIENCE: Patient, Health Professional, Risk Manager, Pharmacy ISSUE: Teligent is recalling one lot of Lidocaine HCl Topical Solution 4%, 50 mL (Lot # 14218, Exp. 09/2022) because the firm's testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 18-month stability timepoint. Use of the super potent product would result in a higher than intended lidocaine dose above that intended.  An increased lidocaine dose could lead to the development of local anesthetic systemic toxicity depending on the duration of the treatment and the specific patient.  Local anesthetic systemic toxicity can result in central nervous system reactions including excitation and/or depression and more serious signs of cardiovascular toxicity, such as bradycardia, hypotension, and even cardiovascular collapse can present very quickly. If local anesthetic systemic toxicity is not recognized and treated quickly, severe morbidity and even death can result. Adults and the elderly who are more likely to use this product as well as children of lower body weight are more likely to experience local anesthetic systemic toxicity if a higher than intended lidocaine concentration is administered. To date, Teligent Pharma has not received any reports of adverse events related to this recall   For more information about this recall, click on the red button "Read Recall" below. BACKGROUND: Lidocaine Hydrochloride Topical Solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. RECOMMENDATIONS:  Patients that have Lidocaine HCl Topical Solution 4% which is being recalled should return product to their place of purchase. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report online. Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA